期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 12, 期 4, 页码 572-578出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00571
关键词
transient receptor potential canonical 3; pyrazole 3; selective inhibitor; high metabolic stability; low toxicity
资金
- NIH [R01GM125629, R01AG049772]
- UTHSC CORNET award
- UTCoP Drug Discovery Center
A series of conformationally restricted Pyr3 analogues were designed, with compound 20 showing high potency and selectivity for human TRPC3 as well as improved metabolic stability and safety compared to Pyr3. Preliminary evaluation demonstrated that 20 could rescue Aβ-induced neuron damage in vitro, indicating its potential as a promising scaffold for ameliorating symptoms associated with TRPC3-mediated neurological and cardiovascular disorders.
The overactivation of transient receptor potential canonical 3 (TRPC3) is associated with neurodegenerative diseases and hypertension. Pyrazole 3 (Pyr3) is reported as the most selective TRPC3 inhibitor, but it has two inherent structural limitations: (1) the labile ester moiety leads to its rapid hydrolysis to the inactive Pyr8 in vivo, and (2) the alkylating trichloroacrylic amide moiety is known to be toxic. To circumvent these limitations, we designed a series of conformationally restricted Pyr3 analogues and reported that compound 20 maintains high potency and selectivity for human TRPC3 over its closely related TRP channels. It has significantly improved metabolic stability compared with Pyr3 and has a good safety profile. Preliminary evaluation of 20 demonstrated its ability to rescue A beta-induced neuron damage with similar potency to that of Pyr3 in vitro. Collectively, these results suggest that 20 represents a promising scaffold to potentially ameliorate the symptoms associated with TRPC3-mediated neurological and cardiovascular disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据